Strs Ohio trimmed its position in CytomX Therapeutics Inc (NASDAQ:CTMX) by 14.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 40,600 shares of the biotechnology company’s stock after selling 7,000 shares during the quarter. Strs Ohio owned approximately 0.11% of CytomX Therapeutics worth $737,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Goldman Sachs Group Inc. bought a new stake in shares of CytomX Therapeutics in the 1st quarter valued at approximately $190,000. KCG Holdings Inc. bought a new stake in shares of CytomX Therapeutics in the 1st quarter valued at approximately $388,000. American Century Companies Inc. bought a new stake in shares of CytomX Therapeutics in the 2nd quarter valued at approximately $922,000. Sphera Funds Management LTD. boosted its position in CytomX Therapeutics by 33.3% during the 2nd quarter. Sphera Funds Management LTD. now owns 200,000 shares of the biotechnology company’s stock valued at $3,100,000 after purchasing an additional 50,000 shares during the period. Finally, TIAA CREF Investment Management LLC boosted its position in CytomX Therapeutics by 183.7% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 169,552 shares of the biotechnology company’s stock valued at $2,628,000 after purchasing an additional 109,791 shares during the period. Institutional investors and hedge funds own 60.02% of the company’s stock.

In other news, CFO Debanjan Ray sold 2,500 shares of the company’s stock in a transaction on Wednesday, August 9th. The stock was sold at an average price of $15.00, for a total value of $37,500.00. Following the completion of the sale, the chief financial officer now owns 19,626 shares in the company, valued at $294,390. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Sean A. Mccarthy sold 14,342 shares of the company’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $19.86, for a total value of $284,832.12. Following the completion of the sale, the chief executive officer now owns 18,587 shares of the company’s stock, valued at approximately $369,137.82. The disclosure for this sale can be found here. Insiders have sold a total of 194,636 shares of company stock valued at $4,140,921 in the last quarter. 8.00% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: “CytomX Therapeutics Inc (CTMX) Shares Sold by Strs Ohio” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/11/07/cytomx-therapeutics-inc-ctmx-shares-sold-by-strs-ohio.html.

CytomX Therapeutics Inc (NASDAQ:CTMX) opened at $20.04 on Tuesday. CytomX Therapeutics Inc has a 12-month low of $9.85 and a 12-month high of $24.67.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.30). CytomX Therapeutics had a negative return on equity of 160.51% and a negative net margin of 288.12%. The business had revenue of $8.75 million for the quarter, compared to analyst estimates of $4.95 million. research analysts predict that CytomX Therapeutics Inc will post -1.46 EPS for the current year.

CTMX has been the subject of a number of analyst reports. Wedbush initiated coverage on CytomX Therapeutics in a research report on Thursday, September 7th. They set an “outperform” rating and a $26.00 price objective for the company. Nomura boosted their price objective on CytomX Therapeutics to $44.00 and gave the company a “buy” rating in a research report on Wednesday, October 4th. Jefferies Group LLC set a $25.00 price objective on CytomX Therapeutics and gave the company a “buy” rating in a research report on Friday, August 25th. ValuEngine lowered CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, September 15th. Finally, Bank of America Corporation boosted their price objective on CytomX Therapeutics from $30.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, October 4th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $31.88.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Want to see what other hedge funds are holding CTMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics Inc (NASDAQ:CTMX).

Institutional Ownership by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Stock Ratings for CytomX Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc and related stocks with our FREE daily email newsletter.